Zydus Lifesciences jumps on getting USFDA’s approval for Pemetrexed for Injection
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 369.85, up by 3.60 points or 0.98% from its previous closing of Rs. 366.25 on the BSE.
The scrip opened at Rs. 368.95 and has touched a high and low of Rs. 372.60 and Rs. 363.80 respectively. So far 47123 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.85 on 11-Jun-2021 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 373.55 and Rs. 334.85 respectively. The current market cap of the company is Rs. 37980.85 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 15.44% and 9.69% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Pemetrexed for Injection, in the strengths of 100 mg/vial, 500 mg/vial, and 1000 mg/vial Single-Dose Vials.
Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells. The drug will be manufactured at Zydus Hospira. Pemetrexed for Injection has a market size of $1,236 million (as per IQVIA MAT March’22).
The group now has 314 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
